MX2023014793A - Codificacion de acido nucleico para la proteína de fusión klk2-gpi, células recombinantes y usos de estos. - Google Patents

Codificacion de acido nucleico para la proteína de fusión klk2-gpi, células recombinantes y usos de estos.

Info

Publication number
MX2023014793A
MX2023014793A MX2023014793A MX2023014793A MX2023014793A MX 2023014793 A MX2023014793 A MX 2023014793A MX 2023014793 A MX2023014793 A MX 2023014793A MX 2023014793 A MX2023014793 A MX 2023014793A MX 2023014793 A MX2023014793 A MX 2023014793A
Authority
MX
Mexico
Prior art keywords
klk2
fusion protein
nucleic acid
recombinant cells
acid coding
Prior art date
Application number
MX2023014793A
Other languages
English (en)
Spanish (es)
Inventor
Stuart L Emanuel
Thomas J Rutkoski
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023014793A publication Critical patent/MX2023014793A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21035—Tissue kallikrein (3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C07K2319/912—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation containing a GPI (phosphatidyl-inositol glycane) anchor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2023014793A 2021-06-10 2022-06-08 Codificacion de acido nucleico para la proteína de fusión klk2-gpi, células recombinantes y usos de estos. MX2023014793A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163209019P 2021-06-10 2021-06-10
PCT/IB2022/055355 WO2022259190A1 (en) 2021-06-10 2022-06-08 Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof

Publications (1)

Publication Number Publication Date
MX2023014793A true MX2023014793A (es) 2024-03-25

Family

ID=82358484

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014793A MX2023014793A (es) 2021-06-10 2022-06-08 Codificacion de acido nucleico para la proteína de fusión klk2-gpi, células recombinantes y usos de estos.

Country Status (11)

Country Link
US (1) US20220403397A1 (cg-RX-API-DMAC7.html)
EP (1) EP4352217A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520790A (cg-RX-API-DMAC7.html)
KR (1) KR20240021211A (cg-RX-API-DMAC7.html)
CN (1) CN117480253A (cg-RX-API-DMAC7.html)
AU (1) AU2022291273A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023025616A2 (cg-RX-API-DMAC7.html)
CA (1) CA3222756A1 (cg-RX-API-DMAC7.html)
IL (1) IL309179A (cg-RX-API-DMAC7.html)
MX (1) MX2023014793A (cg-RX-API-DMAC7.html)
WO (1) WO2022259190A1 (cg-RX-API-DMAC7.html)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5602299A (en) 1992-09-23 1997-02-11 Mount Sinai School Of Medicine Of The City University Of New York Transgenic animal models for neurodegenerative disease
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US6113917A (en) * 1995-04-25 2000-09-05 Rmf Dictagene S.A. Modified polypeptides for enhanced immunogenicity
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
WO2004098529A2 (en) * 2003-04-30 2004-11-18 Emory University Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
JP4549666B2 (ja) * 2003-12-12 2010-09-22 タカラバイオ株式会社 抗体の製造方法
ATE440949T1 (de) * 2004-01-30 2009-09-15 Maxygen Holdings Ltd Gesteuertes überlesen von stopcodons
KR20070084330A (ko) * 2004-10-18 2007-08-24 지모제넥틱스, 인코포레이티드 가용성 zcytor21, 항-zcytor21 항체 및 결합파트너 및 염증에서의 사용방법
EP2315846A4 (en) * 2008-08-05 2011-11-30 Univ Rochester PSA AND KLK2 AS THERAPEUTIC TARGET MOLECULES AND PSA AND KLK2-INHIBITABLE MOLECULES
JP6092782B2 (ja) * 2010-11-16 2017-03-08 エクセリミューン, インコーポレイテッド 組換えタンパク質の製造方法
EP3218477A4 (en) * 2014-11-10 2018-07-18 The Board of Trustees of The Leland Stanford Junior University Compositions and methods for expressing polypeptides on the surface of cells
TW202118792A (zh) * 2019-07-26 2021-05-16 美商健生生物科技公司 抗hk2嵌合抗原受體(car)

Also Published As

Publication number Publication date
BR112023025616A2 (pt) 2024-02-27
EP4352217A1 (en) 2024-04-17
JP2024520790A (ja) 2024-05-24
WO2022259190A1 (en) 2022-12-15
IL309179A (en) 2024-02-01
US20220403397A1 (en) 2022-12-22
AU2022291273A1 (en) 2024-01-25
CA3222756A1 (en) 2022-12-15
CN117480253A (zh) 2024-01-30
KR20240021211A (ko) 2024-02-16

Similar Documents

Publication Publication Date Title
BR9813608A (pt) Polipeptìdeo isolado, sequências de ácido nucleico isolado e mutante, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, processos para produzir uma sequência de ácido nucleico mutante, para produzir um polipeptìdeo, para produzir um mutante de uma célula originária e para produzir uma proteìna, e, célula mutante
DE69914309D1 (de) Tadg15: eine extrazelluläre serinprotease überexprimiert in brust- und eierstock-karzinomen
EP0722461A4 (en) EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT OF CYTOPLASM WITHOUT HEAD SEQUENCE
WO2005017149A8 (en) Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
CA2087261A1 (en) Purification directed cloning of peptides
EA200100419A1 (ru) Трансформационная система в области грибов гифомицетов-хозяев
WO1998056927A3 (en) Nucleic acids encoding polypeptide having protease activity
ES8500325A1 (es) Procedimiento para la preparacion de proteinas funcionales de uroquinasa humana.
ES8802394A1 (es) Un procedimiento para preparar una proteina de fusion derivada de la secuencia de aminoacidos de la preprorrelaxina humana.
MX2025009545A (es) Metodos y composiciones para la administracion de sistemas de vector dual otoferlin
WO1995006735A3 (en) Nucleotide sequences for novel protein tyrosine phosphatases
ATE424457T1 (de) Menschliche stra6 polypeptide
ATE384787T1 (de) Tripeptidyl-aminopeptidase
MX2023002413A (es) Proteinas de fusion inmunogenicas de coronavirus y metodos relacionados.
WO2000068247A3 (en) Serine proteases
ATE357526T1 (de) Modifizierte hcv peptid-impfstoffe
WO2022081728A3 (en) Modified interleukin 2 (il-2) polypeptides, and methods of making and using the same
EP0238473A3 (en) Serine protease inhibitors
DE69635081D1 (de) Enamel-matrix bezogene polypeptide
ATE321842T1 (de) Extrazelluläre serinprotease
Ronne et al. Growth factor‐binding proteases in the murine submaxillary gland: isolation of a cDNA clone.
Horstmann et al. Host tissue destruction by Entamoeba histolytica: molecules mediating adhesion, cytolysis, and proteolysis
DK1546302T3 (da) Fremgangsmåder til fremstilling af pattedyrs-trypsiner
WO2023114831A3 (en) Improvement of dnase1l3 serum half-life
WO2004056316A8 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies